BioSyent Inc. ('BioSyent”, TSX Venture: RX) released today its financial results for the three months (Q3) and nine months ...
Initial results of ongoing investigator-initiated proof-of-concept trial demonstrate crofelemer can potentially extend the lives of infants born with intestinal failure due to microvillus inclusion ...
AI wants to live in your ears, eyes and bedside table. Should you let it? We put the latest gadgets to the test ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback